The Board of Directors of the Company at its meeting held today, i.e., Tuesday, May 19, 2026, inter-alia, considered and approved Audited Standalone and Consolidated Financial Results of ....
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty Microcap 250 and 5.7 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nephrocare Health Services reported audited standalone financial results for Q4 and FY ended March 2026. For the full year, revenue from operations grew 15.8% to Rs. 6,297.43 million from Rs. 5,435.97 million in FY25. However, the company posted a standalone net loss of Rs. 80.60 million for FY26 compared to a net profit of Rs. 342.36 million in FY25, a sharp reversal driven mainly by a non-cash, non-recurring finance cost of Rs. 371.89 million related to FVTPL financial liabilities from the IPO transaction. The Board also approved investment of up to Rs. 10 crore in the Nepal subsidiary and in-principal approval for providing collateral/security support of up to Rs. 70 crore each for the Singapore and Saudi Arabia subsidiaries. BDO India LLP was re-appointed as internal auditor for FY26-27. The statutory auditor (BSR and Co) issued an unmodified (clean) opinion on both standalone and consolidated results.
The swing to a full-year net loss despite revenue growth signals pressure from IPO-related finance costs and rising credit loss allowances (Rs. 133.31 million vs Rs. 26.32 million in FY25). The Rs. 150 crore aggregate exposure for overseas subsidiaries increases contingent liability risk for shareholders. The clean audit opinion provides some comfort on financial reporting integrity.